Sonnet Biotherapeutics Holdings, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Sonnet BioTherapeutics is seeking to register up to 2,000,000 shares of common stock for potential sale by Chardan Capital Markets, aiming to raise up to $25 million through a committed equity facility.
S-1/A: Sonnet BioTherapeutics Files for Resale of Common Stock and Warrants After Private Placements
Sonnet BioTherapeutics is registering for resale 127,500 shares of common stock and 2,303,825 shares issuable upon exercise of warrants, following recent private placements.
Sonnet BioTherapeutics plans to offer and sell up to 2,000,000 shares of common stock through a committed equity facility with Chardan Capital Markets, potentially raising up to $25 million.
Sonnet BioTherapeutics is registering for the resale of up to 127,500 shares of common stock and 2,303,825 shares issuable upon exercise of warrants by selling stockholders.
Sonnet BioTherapeutics plans to offer common stock and warrants to purchase common stock, aiming to raise capital for research and development, working capital, and debt repayment.
Sonnet BioTherapeutics is undertaking a public offering of common stock and warrants to raise capital for research and development, working capital, and general corporate purposes.
Sonnet BioTherapeutics plans to offer shares of common stock and warrants to fund research and development, working capital, and debt repayment.
Sonnet BioTherapeutics is seeking to raise up to $25 million through a committed equity facility with Chardan Capital Markets, potentially diluting existing shareholders.
S-1: Sonnet BioTherapeutics Announces $25 Million Committed Equity Facility with Chardan Capital Markets
Sonnet BioTherapeutics enters into a purchase agreement with Chardan Capital Markets for a committed equity facility of up to $25 million.